Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tourmaline Bio Inc. (TRML)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TRML (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 43.75% | Avg. Invested days 34 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 428.51M USD | Price to earnings Ratio - | 1Y Target Price 56.44 |
Price to earnings Ratio - | 1Y Target Price 56.44 | ||
Volume (30-day avg) 322557 | Beta - | 52 Weeks Range 11.87 - 29.79 | Updated Date 04/1/2025 |
52 Weeks Range 11.87 - 29.79 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.89 |
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.87 | Actual -0.86 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.6% | Return on Equity (TTM) -28.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 131845812 | Price to Sales(TTM) - |
Enterprise Value 131845812 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -281.95 | Shares Outstanding 25685400 | Shares Floating 15577956 |
Shares Outstanding 25685400 | Shares Floating 15577956 | ||
Percent Insiders 22.58 | Percent Institutions 85.74 |
Analyst Ratings
Rating 4.62 | Target Price 57.29 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tourmaline Bio Inc.
Company Overview
History and Background
Tourmaline Bio, Inc. is a late-stage clinical biopharmaceutical company focused on developing transformative medicines to benefit patients with debilitating diseases. Founded in 2022, the company is relatively new and rapidly advancing its lead asset, TOUR006, an anti-IL-6 antibody.
Core Business Areas
- Drug Development: Focuses on the research and development of novel therapeutics, particularly TOUR006, for autoimmune and inflammatory diseases.
Leadership and Structure
The company is led by a management team with experience in drug development and biotechnology. Specific details on the complete organizational structure are not publicly available.
Top Products and Market Share
Key Offerings
- TOUR006: TOUR006 is Tourmaline Bio's lead product candidate, a fully human, high affinity anti-IL-6 antibody being developed for Thyroid Eye Disease (TED) and other autoimmune and inflammatory conditions. As a clinical stage product, there is no current market share or revenue. Competitors in the IL-6 pathway include Roche (Actemra) and Sanofi (Kevzara).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and characterized by rapid technological advancements. The autoimmune and inflammatory disease market is substantial and growing, driven by unmet medical needs and aging populations.
Positioning
Tourmaline Bio aims to establish itself as a key player in the autoimmune and inflammatory disease market through its novel anti-IL-6 antibody, TOUR006. Its competitive advantage lies in the potential for improved efficacy and safety compared to existing IL-6 inhibitors.
Total Addressable Market (TAM)
The total addressable market for IL-6 inhibitors in autoimmune and inflammatory diseases is estimated to be billions of dollars annually. Tourmaline Bio is targeting specific indications like Thyroid Eye Disease (TED) and others, hoping to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (TOUR006)
- Experienced management team
- Strong financial backing
- Focus on high unmet medical needs
Weaknesses
- Single product pipeline (TOUR006)
- Clinical stage development risk
- Limited commercial infrastructure
Opportunities
- Expansion into new indications for TOUR006
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from established IL-6 inhibitors
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- RHHBY
- SNY
Competitive Landscape
Tourmaline Bio faces competition from established pharmaceutical companies with approved IL-6 inhibitors. Its competitive advantage depends on demonstrating superior efficacy and safety with TOUR006.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Tourmaline Bio's historical growth is characterized by the rapid advancement of TOUR006 through clinical development.
Future Projections: Future growth is contingent on positive clinical trial results and successful commercialization of TOUR006.
Recent Initiatives: Recent initiatives include initiating and progressing clinical trials for TOUR006 in various indications.
Summary
Tourmaline Bio is a clinical-stage company with a promising lead candidate, TOUR006, targeting autoimmune and inflammatory diseases. Its success hinges on positive clinical trial outcomes and navigating a competitive landscape. The company's strengths lie in its novel therapeutic approach and experienced management. However, it faces risks associated with clinical development and competition from established players.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
ARWR
Arrowhead Pharmaceuticals Inc
ARWR
Arrowhead Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tourmaline Bio Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-05-07 | Co-Founder, CEO & Director Dr. Sandeep C. Kulkarni M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.tourmalinebio.com |
Full time employees 74 | Website https://www.tourmalinebio.com | ||
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.